These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 20718912)
41. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis. Ouyang Q; Duan Z; Lei J; Jiao G Tumour Biol; 2016 Mar; 37(3):2999-3007. PubMed ID: 26415734 [TBL] [Abstract][Full Text] [Related]
42. 18F-FDG PET/CT for staging of penile cancer. Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528 [TBL] [Abstract][Full Text] [Related]
43. Diagnostic accuracy of (18) F-methylcholine positron emission tomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma. Bieze M; Klümpen HJ; Verheij J; Beuers U; Phoa SS; van Gulik TM; Bennink RJ Hepatology; 2014 Mar; 59(3):996-1006. PubMed ID: 24123111 [TBL] [Abstract][Full Text] [Related]
44. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129 [TBL] [Abstract][Full Text] [Related]
45. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714 [TBL] [Abstract][Full Text] [Related]
47. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer]. García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948 [TBL] [Abstract][Full Text] [Related]
48. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082 [TBL] [Abstract][Full Text] [Related]
49. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965 [TBL] [Abstract][Full Text] [Related]
50. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study. Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552 [TBL] [Abstract][Full Text] [Related]
52. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171 [TBL] [Abstract][Full Text] [Related]
53. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Schmid DT; John H; Zweifel R; Cservenyak T; Westera G; Goerres GW; von Schulthess GK; Hany TF Radiology; 2005 May; 235(2):623-8. PubMed ID: 15858102 [TBL] [Abstract][Full Text] [Related]